Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  € $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Drug Delivery Partnering Terms and Agreements

Enquire | Email | Print

Published Date: Jan, 2014
Format: PDF
No of Pages: 2427

 
 
Select pricing :
Change Currency: € EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 2,500 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2007.
In addition, a comprehensive appendix is provided organized by drug delivery partnering company A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.

Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into by leading companies worldwide.

Drug Delivery Partnering Terms and Agreements includes:

-Trends in drug delivery dealmaking in the biopharma industry since 2007
-Analysis of drug delivery deal structure
-Access to headline, upfront, milestone and royalty data
-Case studies of real-life drug delivery deals
-Access to over 2,500 drug delivery contract documents
-The leading drug delivery deals by value since 2007
-Most active drug delivery dealmakers since 2007
-The leading drug delivery partnering resources

In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:

-Company A-Z
-Headline value
-Stage of development at signing
-Deal component type
-Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Drug Delivery Partnering Terms and Agreements provides the reader with the following key benefits:

-In-depth understanding of drug delivery deal trends since 2007
-Access to headline, upfront, milestone and royalty data
-Analysis of the structure of drug delivery agreements with numerous real life case studies
-Comprehensive access to over 2,500 actual drug delivery contracts entered into by the world’s biopharma companies
-Detailed access to actual drug delivery contracts enter into by the leading fifty big pharma and big biotech companies
-Insight into the terms included in a drug delivery agreement, together with real world clause examples
-Understand the key deal terms companies have agreed in previous deals
-Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery partnering over the years
2.3. Big pharma drug delivery dealmaking activity
2.4. Big biotech drug delivery dealmaking activity
2.5. Most active drug delivery dealmakers
2.6 Drug delivery partnering by deal type
2.7. Drug delivery partnering by disease type
2.8. Partnering by drug delivery technology type
2.9. Average deal terms for drug delivery partnering
2.9.1 Drug delivery headline values
2.9.2 Drug delivery upfront payments
2.9.3 Drug delivery milestone payments
2.9.4 Drug delivery royalty rates
2.10. The anatomy of drug delivery partnering
2.11. Drug delivery or specialty pharma?
2.11.1. Is specialty pharma the only way for drug delivery?
2.11.2. Best practice for optimizing drug delivery program development
2.11.3. The anatomy of a drug delivery deal
2.11.3.a. Case study 1: Uluru – Oradisc
2.11.3.b. Case study 2: Bayer – MDRNA
2.11.3.c. Case study 3: Endo Pharmaceuticals – BioDelivery Sciences

Chapter 3 – Leading drug delivery deals
3.1. Introduction
3.2. Top drug delivery deals by value
Chapter 4 – Big pharma drug delivery deals
4.1. Introduction
4.2. How to use big pharma drug delivery partnering deals
4.3. Big pharma drug delivery partnering company profiles
Abbott
Actavis
Actavis (Acquired by Watson)
Allergan
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy Laboratories
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 5 – Big biotech drug delivery deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech drug delivery partnering company profiles
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
AMAG Pharmaceuticals
Amgen
Array Biopharma
Biocon
Biogen Idec
BioMarin Pharmaceuticals
Cangene
Celgene
Cubist
Dendreon
Elan
Emergent BioSolutions
Galapagos
Gilead Sciences
Grifols
Ipsen
Isis Pharmaceuticals
LFB Group
Morphosys
Nektar Therapeutics
Novo Nordisk
NPS Pharmaceuticals
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
SciClone Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
United Therapeutics
Vertex Pharmaceuticals
ViroPharma

Chapter 6 – Drug delivery partnering contracts directory
6.1. Introduction
6.2. Company A-Z
3M
3M Drug Delivery Systems
3SBio
Abbott Laboratories
Abraxis BioScience
Accentia Biopharmaceuticals
Accredo Health Group
Acorda Therapeutics
Actavis
Actient Pharmaceuticals
Acura Pharmaceuticals
Acusphere
Adams Respiratory Therapeutics
Adeona Pharmaceuticals
Adolor
Advanced Life Sciences
Alchemia
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alfacell
Alimera Sciences
Alkermes
Allergan
Allos Therapeutics
Alnylam Pharmaceuticals
Alpharma
Alpharma Ireland
Altus Pharmaceuticals
Amag Pharmaceuticals
Amarillo Biosciences
Amarin
Amicus Therapeutics
Ampio Pharmaceuticals
Amylin Pharmaceuticals
Anacor Pharmaceuticals
ANDRx
Anesiva
Anesta
Angiodynamics
Angiotech Pharmaceuticals
AnorMed
AP Pharma
Aradigm
Aristos Pharmaceuticals
Arius Pharmaceuticals
ArQule
Arrow International
ARYx Therapeutics
Astellas
AstraZeneca
Atley Pharmaceuticals
Auxilium Pharmaceuticals
AVANT Immunotherapeutics
AVI Pharma
Azur Pharma
Banner Pharmacaps
Barrier Therapeutics
Bausch & Lomb
Baxter Healthcare
Baxter Oncology GmbH
Bayer
Bayer Healthcare
Ben Venue Laboratories
Bentley Pharmaceuticals
Biken
BioAlliance Pharma
BioArray Solutions
BioCryst Pharmaceuticals
BioDelivery Sciences
Biofield
Biogen Idec
BiolineRX
Biomedical Advanced Research and Development Authority
BioMerieux
BioMimetic Therapeutics
Biopure
BioSante Pharmaceuticals
BioSpecifics Technologies
Biovail
Biovail Laboratories
BioVest
BioZone Laboratories
Brand Builders International
Brand Builders Rx
Breath
Bristol-Myers Squibb
Brookwood Pharmaceuticals
Brotech
Caleco Pharma
Caleco Pharma Europe
Callisto Pharmaceuticals
Cambridge Laboratories
Caraco Pharmaceuticals
Cardinal Health
Cardium Therapeutics
Cary Pharmaceuticals
Catalent Pharma Solutions
Cato BioVentures
Celsion
Cephalon
Cepheid
Cerus
Chrysalis Technologies
Clarus Therapeutics
Coating Place
CollaGenex
Columbia Laboratories
CombinatoRx
Contract Pharmaceuticals
Control Delivery Systems
CorMedix
Cornerstone Biopharma
Cornerstone Therapeutics
Cortex Pharmaceuticals
Cosmo Technologies
Cowen Healthcare Royalty Partners
CP Pharmaceuticals
CPEX Pharmaceuticals
Crawford Healthcare
Critical Therapeutics
Cubist Pharmaceuticals
Cumberland Pharmaceuticals
CV Therapeutics
CyDex
Cypress Bioscience
Daewoong Pharmaceutical
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dalian Wande Electronics
Dechra Veterinary Products
Defense Threat Reduction Agency
Dehaier Medical Systems
Department of Homeland Security
DepoMed
Desitin
Dey Pharma
Diomed
Discovery Laboratories
DoctorDirectory
DOR BioPharma
Dov Pharmaceutical
Dow Pharmaceutical Sciences
DPT Laboratories
Draxis Pharma
Drugs for Neglected Diseases Initiative
Duramed
Durect
DUSA Pharmaceuticals
Dyax
Echo Therapeutics
ECR Pharmaceuticals
EDK Therapeutics
EKR Therapeutics
Elan
Eli Lilly
Elite Pharmaceuticals
Emergent BioSolutions
Emisphere
Endo Pharmaceuticals
Enzon Pharmaceuticals
Epic Pharmaceuticals
EpiCept
Esprit Pharma
Evonik Industries
Facet Biotechnology
Ferndale Pharmaceuticals
Finorga
Fleet Laboratories
Flynn Pharma
Forbes Medi-Tech
Fovea Pharmaceuticals
Genaera
Genentech
Generex Biotechnology
Genta
GenVec
Genzyme
Ghent University
GlaxoSmithKline
GlobeImmune
GPC Biotech
Graceway Pharmaceuticals
Green Vision
Grunenthal
Hadasit Medical Research Services and Development
Halozyme Therapeutics
Hangzhou Zhencheng Pharmaceuticals
Hebei Huaxing Pharmaceuticals
Hebei Kiwa Huaxing Bio-Pharmaceuticals
Helix BioMedix
Helix BioPharma
HemispheRx Biopharma
Heraeus
Hermes BioScience
Horizon Pharma AG
Horizon Pharma Inc
Hospira
Hunan Jiuwang Pharmaceuticals
Hydron Technologies
Idea
IDIS Pharma
Ikaria
ImaRX
ImClone Systems
Immunomedics
Impax Laboratories
Imprimis Pharmaceuticals
Inalco Biochemicals
Inalco Group
Incyte
Indevus Pharmaceuticals
Inex Pharmaceuticals
Inovio Pharmaceuticals
InSite Vision
Insmed Inc
Inspire Pharmaceuticals
Institut Biochimique
Intas Biopharmaceuticals
IntelGenx
Intendis
Intergen
InterMune
Ipsen
ISTA Pharmaceuticals
Ivax
Jagotec
Javelin Pharmaceuticals
Jazz Pharmaceuticals
JDS Pharmaceutical
JHP Pharmaceuticals
Jiangsu Yabang Pharmaceuticals
Johns Hopkins University
Johnson & Johnson
JPI Commercial
KCI International
Kensey Nash
Keryx Biopharmaceuticals
King Pharmaceuticals
Kiwa Bio-Tech Products
Klarogen Biotherapeutics
Kunwha Pharmaceuticals
KV Pharmaceutical
Kyowa Hakko Kogyo
Kythera Biopharmaceuticals
Lees Pharmaceutical
Lenetix
Ligand Pharmaceuticals
Lonza
Los Angeles Biomedical Research Institute
Lung Rx
Lupin Pharmaceuticals
Macrochem
Mallinckrodt
MAP Pharmaceuticals
Marina Biotech
Massachusetts Institute of Technology
McCoy Enterprises
McKesson
McNeil PPC
MD Anderson Cancer Center
MDRNA
Meda
Medgenics
Medical Futures
MediciNova
Medicis
Medtronic
Meiji Seika
Memorial Sloan Kettering Cancer Center
Memory Pharmaceuticals
Menarini
Merck and Co
Merial
Merrimack Pharmaceuticals
Mglas
Microbix Biosystems
MiddleBrook Pharmaceutical
Mikah Pharma
Millennium
Mist Acquisition
Mova Pharmaceuticals
Mundipharma
Mutual Pharmaceutical
Mylan Laboratories
National Institute of Allergy and Infectious Diseases
National Institute of Infectious Diseases
ND Partners
Nektar Therapeutics
Neos Therapeutics
NeurogesX
Neurokine Pharmaceuticals
Neuromed
NeuroMed Devices
Neuronex
NexMed
Nitec Pharma
NitroMed
Nof
Norgine
Northern Lipids
Nova Biomedical
NovaBay Pharmaceuticals
NovaCardia
Novacea
NovaDel Pharma
Novartis
Novartis Consumer Health
Novasep
Noven Pharmaceuticals
Novo Nordisk
Novozymes Biopharma
NuGlow Cosmaceuticals
NuPathe
Nycomed
Obagi Medical Products
Ocimum Biosolutions
Oculus Innovative Sciences
Oklahoma Medical Research Foundation
OncoSec Medical
Ono Pharmaceutical
Ophthalmic Research Associates
Oradisc
Oramed Pharmaceuticals
Ore Pharmaceuticals
Orexigen Therapeutics
Orion
Oso Bio Pharmaceuticals
Pacific Beach Biosciences
Pacira Pharmaceuticals
Paladin Labs
Panion
Par Pharmaceutical
Paramount Biosciences
Patheon
PDL BioPharma
Pfizer
Pharmaceutical Innovations
Pharmacopeia
PharmaEngine
Philip Morris Products
Pipex Pharmaceuticals
Polymun Scientific Immunbiologische
Poniard Pharmaceuticals
Porex
Pozen
Prasco Laboratories
Precision Pharma Services
Prestige Brands
Procter & Gamble
Procter & Gamble Pharmaceuticals
Professional Compounding Centers of America
Progenics Pharmaceuticals
Proteolix
PSivida
Purdue Pharma
QLT
QLT USA
QuatRx Pharmaceuticals
Radius Health
Rechon Life Sciences
Reckitt Benckiser
RedHill Biopharma
Repligen
RevImmune
Rib-X Pharmaceuticals
Rigel Pharmaceuticals
Roche
Rodan and Fields
Rohto Pharmaceuticals
Royalty Securitization Trust
S2 Therapeutics
Sagent Pharmaceuticals
Salix Pharmaceuticals
Sam Amer
Sangamo BioSciences
Sanofi-Aventis
Santarus
Santen Pharmaceutical
Savient Pharmaceuticals
Schering-Plough
Scolr Pharma
Seattle Genetics
Select Vaccines
Senetek
Sepracor
Sequenom
Serenity Pharmaceuticals
Shaanxi Aoxing Pharmaceutical
Shaanxi Jiali Pharmaceuticals
Shandong Yaoshan Pharmaceuticals
Shijiazhuang-Unigene Pharmaceuticals
Shijiazhuang Pharmaceutical
Shionogi
Shire Pharmaceuticals
SIGA Technologies
Sigma-Aldrich
Sigma-Tau
SignPath Pharmaceuticals
SK Biopharmaceuticals
SkyePharma
SLA Pharma
Solvay
Southern Research Institute
Sovereign Pharmaceuticals
Spectrum Pharmaceuticals
Spring Creek Capital
SRI International
Strakan
Strativa Pharmaceuticals
Sun Pharmaceutical
Sunovion Pharmaceuticals
SurModics
SurModics Pharmaceuticals
Symphony Allegro
Takeda Pharmaceutical
Tanabe Seiyaku
Targanta Therapeutics
Tarsa Therapeutics
Teikoku Pharma USA
Teikoku Seiyaku
Tekmira Pharmaceuticals
Tercica
Teva Pharmaceuticals
The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center
The Medicines Company
The Regents of the University of California
Therabel
TPG Capital
Transcept Pharmaceuticals
Transdel Pharmaceuticals
Transition Therapeutics
Tranzyme Pharma
Triax Aesthetics
Tris Pharma
TTY Biopharm
UCB
Uluru
Unigene Labs
United Therapeutics
Valeant Pharmaceuticals
Vanda Pharmaceuticals
Ventrus Biosciences
VeroScience
VetCure
VIA Pharmaceuticals
Victory Pharma
Viropharma
Vivus
WA 32609
Wanbang Anesiva (Jiangsu) Biotech
Wanbang Biopharmaceuticals
Warner Chilcott
Washington Research Foundation
Watson Laboratories
Watson Pharmaceuticals
Wockhardt
Wyeth
Xianyang Materia Medica
Xi’an Zaolutang Kushidai Pharmaceuticals
XTL Biopharmaceuticals
Yakult Honsha
Yamasa
Zogenix
ZymoGenetics
6.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
6.4. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
6.5. By therapy area
Anaesthetics
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Pediatrics
Psychiatry
Public Health
Respiratory
Sexual Health

Chapter 7 – Drug delivery dealmaking by technology type
7.1. Introduction
7.2. Deals by drug delivery type
Drug delivery
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering

Appendices

Introduction

Appendix 1 – Directory of drug delivery deals by company A-Z 2007-2012

Appendix 2 – Directory of drug delivery deals by stage of development 2007-2012

Appendix 3 – Directory of drug delivery deals by deal type 2007-2012

Appendix 4 – Directory of drug delivery deals by therapy area 2007-2012

Appendix 5 – Drug delivery partnering resource center
Online drug delivery partnering
Drug delivery partnering events
Further reading on drug delivery dealmaking

Table of Figures

Figure 1: Drug delivery partnering since 2007
Figure 2: Big pharma – top 50 – drug delivery deals 2007 to 2013
Figure 3: Big pharma drug delivery deal frequency – 2007 to 2013
Figure 4: Big biotech – top 50 – drug delivery deals 2007 to 2013
Figure 5: Big biotech drug delivery deal frequency – 2007 to 2013
Figure 6: Active drug delivery dealmaking activity– 2007 to 2013
Figure 7: Drug delivery partnering by deal type since 2007
Figure 8: Drug delivery partnering by disease type since 2007
Figure 9: Drug delivery partnering by technology type since 2007
Figure 10: Drug delivery deals with a headline value
Figure 11: Drug delivery deal headline value distribution, US$million – discovery stage
Figure 12: Drug delivery deal headline value distribution, US$million – preclinical stage
Figure 13: Drug delivery deal headline value distribution, US$million – phase I stage
Figure 14: Drug delivery deal headline value distribution, US$million – phase II stage
Figure 15: Drug delivery deal headline value distribution, US$million – phase III stage
Figure 16: Drug delivery deal headline value distribution, US$million – regulatory stage
Figure 17: Drug delivery deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2013
Figure 19: Drug delivery deals with upfront payment values
Figure 20: Drug delivery deal upfront payment distribution, US$million – discovery stage
Figure 21: Drug delivery deal upfront payment distribution, US$million – preclinical stage
Figure 22: Drug delivery deal upfront payment distribution, US$million – phase I stage
Figure 23: Drug delivery deal upfront payment distribution, US$million – phase II stage
Figure 24: Drug delivery deal upfront payment distribution, US$million – phase III stage
Figure 25: Drug delivery deal upfront payment distribution, US$million – regulatory stage
Figure 26: Drug delivery deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2013
Figure 28: Drug delivery deals with milestone payments
Figure 29: Drug delivery deal milestone distribution, US$million – discovery stage
Figure 30: Drug delivery deal milestone distribution, US$million – preclinical stage
Figure 31: Drug delivery deal milestone distribution, US$million – phase I stage
Figure 32: Drug delivery deal milestone distribution, US$million – phase II stage
Figure 33: Drug delivery deal milestone distribution, US$million – phase III stage
Figure 34: Drug delivery deal milestone distribution, US$million – regulatory stage
Figure 35: Drug delivery deal milestone distribution, US$million – marketed stage
Figure 36: Drug delivery deals with royalty rates, %
Figure 37: Drug delivery deal royalty rate distribution, US$million – discovery stage
Figure 38: Drug delivery deal royalty rate distribution, US$million – preclinical stage
Figure 39: Drug delivery deal royalty rate distribution, US$million – phase I stage
Figure 40: Drug delivery deal royalty rate distribution, US$million – phase II stage
Figure 41: Drug delivery deal royalty rate distribution, US$million – phase III stage
Figure 42: Drug delivery deal royalty rate distribution, US$million – regulatory stage
Figure 43: Drug delivery deal royalty rate distribution, US$million – marketed stage
Figure 44: Summary median royalty rate by stage of development, 2007-2013
Figure 45: Components of the typical drug delivery deal structure
Figure 46: Best practice for drug delivery program development
Figure 47: Top drug delivery deals by value since 2007

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 348528, price: INR 200678, CurrentPartnering

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online